455 related articles for article (PubMed ID: 11057850)
1. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
Veiga F; Escribá A; Maluenda MP; López Rubio M; Margalet I; Lezana A; Gallego J; Ribera JM
Thromb Haemost; 2000 Oct; 84(4):559-64. PubMed ID: 11057850
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients.
Mazokopakis EE; Vrentzos GE; Ganotakis ES
Curr Med Res Opin; 2003; 19(6):565-6. PubMed ID: 14594529
[TBL] [Abstract][Full Text] [Related]
4. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F;
Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210
[TBL] [Abstract][Full Text] [Related]
5. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
Bergmann JF; Neuhart E
Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
[TBL] [Abstract][Full Text] [Related]
6. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
7. Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism.
Castro DJ; Díaz G; Martí D; Escobar C; Ortega J; García-Rull S; Picher J; Sueiro A
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):173-7. PubMed ID: 17287635
[TBL] [Abstract][Full Text] [Related]
8. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group.
Colwell CW; Spiro TE; Trowbridge AA; Stephens JW; Gardiner GA; Ritter MA
Clin Orthop Relat Res; 1995 Dec; (321):19-27. PubMed ID: 7497668
[TBL] [Abstract][Full Text] [Related]
11. The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination.
Perhoniemi V; Vuorinen J; Myllynen P; Kivioja A; Lindevall K
Ann Chir Gynaecol; 1996; 85(4):359-63. PubMed ID: 9014067
[TBL] [Abstract][Full Text] [Related]
12. [Low-molecular-weight heparin without oral anticoagulants for the treatment of deep vein thrombosis].
Alonso Martínez JL; Abínzano Guillén ML; Urbieta Echezarreta MA; Annichérico Sánchez FJ; Fernández Ladrón V; García Sanchotena JL
An Med Interna; 2008 Jan; 25(1):4-8. PubMed ID: 18377187
[TBL] [Abstract][Full Text] [Related]
13. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.
Brandjes DP; Heijboer H; Büller HR; de Rijk M; Jagt H; ten Cate JW
N Engl J Med; 1992 Nov; 327(21):1485-9. PubMed ID: 1406880
[TBL] [Abstract][Full Text] [Related]
14. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
[TBL] [Abstract][Full Text] [Related]
16. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
Agnelli G; Prandoni P; Santamaria MG; Bagatella P; Iorio A; Bazzan M; Moia M; Guazzaloca G; Bertoldi A; Tomasi C; Scannapieco G; Ageno W;
N Engl J Med; 2001 Jul; 345(3):165-9. PubMed ID: 11463010
[TBL] [Abstract][Full Text] [Related]
17. Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients.
Arnold JD; Dart BW; Barker DE; Maxwell RA; Burkholder HC; Mejia VA; Smith PW; Longley JM
Am Surg; 2010 Jun; 76(6):563-70. PubMed ID: 20583509
[TBL] [Abstract][Full Text] [Related]
18. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
Marlovits S; Striessnig G; Schuster R; Stocker R; Luxl M; Trattnig S; Vécsei V
Arthroscopy; 2007 Jul; 23(7):696-702. PubMed ID: 17637403
[TBL] [Abstract][Full Text] [Related]
19. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
Charbonnier BA; Fiessinger JN; Banga JD; Wenzel E; d'Azemar P; Sagnard L
Thromb Haemost; 1998 May; 79(5):897-901. PubMed ID: 9609216
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis.
López-Beret P; Orgaz A; Fontcuberta J; Doblas M; Martinez A; Lozano G; Romero A
J Vasc Surg; 2001 Jan; 33(1):77-90. PubMed ID: 11137927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
